Nadia Arnaudo

Nadia Arnaudo has a diverse work experience in the field of molecular biology, with a focus on biochemistry, structural characterization, and drug discovery. Nadia started their career at Università del Piemonte Orientale, where they completed a Master Thesis Project on the identification and characterization of a new Ubiquitin Binding Domain in RNF168, a E3 ligase involved in the DNA damage response. Nadia then pursued a Bachelor's Degree in Biotechnology at Universita' del Piemonte Orientale, where their research focused on investigating the role of Diacylglycerol Kinase α in vesicular traffic from ER to Golgi.

Nadia's research experience continued at the MRC Laboratory of Molecular Biology (LMB), where they completed a research internship before joining the University of Cambridge as a PhD student at the MRC-Laboratory of Molecular Biology. Their PhD project involved biochemical and structural characterization of Sir3 and its binding to the nucleosome, which plays an important role in yeast transcriptional silencing. Nadia achieved personal accomplishments in optimizing protocols for large-scale reconstitution of nucleosomes and developing a new method for purifying protein-nucleosome complexes with higher yields and homogeneity.

In 2013, Nadia had a brief visiting PhD student position at Institut Curie. Nadia then joined Mission Therapeutics in 2014, initially as a scientist in the PLATFORM/ASSAY DEVELOPMENT TEAM, where they contributed to the setup of a platform for a new discovery program. This work resulted in the identification of several potent drug-like molecules for a new family of targets. Nadia gradually moved up the ranks, serving as a Senior Scientist from 2017 to 2021, and currently holds the position of Principal Scientist since 2022.

Nadia Arnaudo pursued their education in the field of science and biotechnology. Nadia obtained their Bachelor's degree in Biotechnology from the Università degli Studi del Piemonte Orientale in 2007. Following that, they completed their Master's degree in Pharmaceutical Biotechnology from the same university between 2007 and 2009. Nadia further advanced their education by pursuing a Doctor of Philosophy (PhD) in Molecular Biology at the University of Cambridge from 2010 to 2014.